BiotechTube

ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Refractory Aggressive B-cell Lymphomas

Conditions

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma

Trial Timeline

Mar 1, 2023 → Mar 1, 2029

NCT ID
NCT05583149

About ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy

ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy is a phase 2 stage product being developed by Johnson & Johnson for Refractory Aggressive B-cell Lymphomas. The current trial status is active. This product is registered under clinical trial identifier NCT05583149. Target conditions include Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL.

What happened to similar drugs?

6 of 20 similar drugs in Refractory Aggressive B-cell Lymphomas were approved

Approved (6) Terminated (1) Active (13)
✅Acalabrutinib capsuleAstraZenecaApproved
✅RuxolitinibNovartisApproved
✅Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + DexamethasoneAmgenApproved
✅clobazam (Onfi) + Initial conversion and titration + Conversion schedule - Week 1 + Conversion schedule - Week 2 + Conversion schedule - Week 3LundbeckApproved
✅SabrilLundbeckApproved
✅BexaroteneBausch HealthApproved
🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05583149Phase 2Active

Competing Products

20 competing products in Refractory Aggressive B-cell Lymphomas

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
mRNA-2416ModernaPhase 2
0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
Valemetostat TosylateDaiichi SankyoPhase 2
39
EnzalutamideAstellas PharmaPhase 2
35
ASP1650Astellas PharmaPhase 2
35
YM598Astellas PharmaPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
39
Lenvatinib + EverolimusEisaiPhase 1/2
32
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
40
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
32
perampanelEisaiPhase 2
35
rabeprazole sodiumEisaiPre-clinical
26
LenvatinibEisaiPhase 2
35